Bayspair has developed a proprietary engineered nuclease to replace CRISPR/Cas9. As with conventional techniques, it is possible to destroy or insert sequences at targeted sites with guide RNA. The rights to this nuclease are 100% owned by the company and can be licensed for all areas including research applications as well as industrial and clinical applications for therapeutics. All genome editing services offered use this nuclease system. Therefore, the resulting cells will not be limited in their use by licensing issues with third party genome editing technologies.
Introduction of nuclease and guide RNA into cells causes sequence deletion via NHEJ or MMEJ pathways. Compared to CRISPR/Cas9, fewer single nucleotide insertions and relatively larger sequence deletions are observed, likely due to MMEJ-predominant editing.
Donor DNA is introduced alongside nuclease and guide RNA. The sequence flanked by homology arms is inserted at the target site via the HDR pathway. Lower probability than knockout, but achieves highly precise sequence integration.